We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain Cancer
News

Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain Cancer

Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain Cancer
News

Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Currently there is no cure for GBM and patients have an average life expectancy of 18 months after diagnosis.

The trial's lead site is the University of Virginia, under Principal Investigator Dr. James Larner, Chairman and Professor of Radiation Oncology. Up to 19 additional institutions in the United States will participate in the trial.

"TSC has demonstrated safety in early human testing as well as significant efficacy in animal studies of brain cancer led by Dr. Jason Sheehan, Professor of Neurosurgery at the UVA," said Dr. Larner. "This trial will test TSC's safety and effectiveness when combined with standard of care treatment, offering a novel and promising clinical trial option for newly diagnosed GBM patients."

The standard treatment for GBM includes surgical removal of the tumor bulk, followed by radiation and chemotherapy. Factors within the tumor micro-environment are thought to account for tumor recurrence, often within months. TSC, which received FDA Orphan Drug designation in July, 2011, enhances oxygen diffusion into this micro-environment, potentially making treatment-resistant tumor cells up to three times more responsive to standard treatments.

Advertisement